News from moonlake immunotherapeutics ag
A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages
06 May, 2021, 12:00 BST MoonLake Immunotherapeutics announces publication in The Lancet of impressive Phase 2b data showing its Tri-specific Nanobody® Sonelokimab totally clears skin in almost 6 out of 10 patients with moderate to severe psoriasis
Sonelokimab showed significant clinical benefit with rapid onset and a good safety profile, with clear skin (PASI 100) achieved in up to 57% of...
03 May, 2021, 13:00 BST MoonLake Immunotherapeutics in-licenses potentially best-in-class Tri-specific Nanobody®, Sonelokimab (M1095/ALX 0761) from Merck KGaA, Darmstadt, Germany, with goal of transforming treatment of inflammatory diseases driven by IL-17A and F
MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint...